LaCasce A et al. Proc ASH 2014;Abstract 293.

Slides:

Advertisements

Similar presentations

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Illidge T et al. Proc ASH 2011;Abstract.

Advertisements

Gopal AK et al. Proc ASH 2013;Abstract 4382.

Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Brown JR et al. Proc ASH 2013;Abstract 523.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Goede V et al. Proc ASCO 2013;Abstract 7004.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.

Palumbo A et al. Proc ASH 2012;Abstract 446.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Bosch F et al. Proc ASH 2014;Abstract 3345.

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

FDG-PET Adapted Sequential Therapy with Brentuximab Vedotin and Augmented ICE Followed by Autologous Stem Cell Transplant for Relapsed and Refractory Hodgkin.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.

Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.

Viardot A et al. Proc ASH 2014;Abstract 4460.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Ruan J et al. Proc ASH 2013;Abstract 247.

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Locatelli F et al. Proc ASH 2013;Abstract 4378.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.

A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple.

Vose JM et al. Proc ASH 2011;Abstract 661.

Moskowitz CH et al. Proc ASH 2015;Abstract 182.

Chen R et al. Proc ASH 2015;Abstract 518.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Shustov AR et al. Proc ASH 2010;Abstract 961.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Oki Y et al. Proc ASH 2013;Abstract 252.

Goede V et al. Proc ASH 2014;Abstract 3327.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Ferrajoli A et al. Proc ASH 2010;Abstract 1395.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Patient charactaristics:

Ansell SM et al. Proc ASH 2012;Abstract 798.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Zaja F et al. Proc ASH 2010;Abstract 966.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Advani RH et al. Proc ASH 2011;Abstract 443.

Presentation transcript:

LaCasce A et al. Proc ASH 2014;Abstract 293. Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma Who Are Relapsed or Refractory After Frontline Therapy LaCasce A et al. Proc ASH 2014;Abstract 293.

Background Salvage chemotherapy with or without autologous stem cell transplant (ASCT) is the standard of care for patients with relapsed/refractory Hodgkin lymphoma (HL) after front-line therapy. Patients who achieve complete remission on salvage chemotherapy regimens prior to ASCT have improved outcomes, although the regimens are associated with significant toxicities. Brentuximab vedotin (B-vedotin)1 and bendamustine2 are highly active with manageable safety profiles as single agents for patients with HL who experience relapse after ASCT (1 JCO 2012;30:2183-9; 2 JCO 2013;31:456-60). Study objective: Evaluate the safety and efficacy of B-vedotin in combination with bendamustine in patients with HL in first relapse. LaCasce A et al. Proc ASH 2014;Abstract 293.

Phase I/II Study Design Eligibility Classical HL Relapsed or refractory after front-line therapy Phase I: Safety (n = 10) Bendamustine IV, 90 mg/m2* d1,2 + B-vedotin IV, d1, 1.8 mg/kg q3wk, up to 6 cycles Phase II: Expansion (n = 40+) Bendamustine IV at selected dose + B-vedotin, 1.8 mg/kg * De-escalated if ≥4/10 patients had dose-limiting toxicity during cycle 1 ASCT any time after cycle 2 Post-transplant, B-vedotin monotherapy, up to 16 total doses LaCasce A et al. Proc ASH 2014;Abstract 293.

Adverse Events No dose-limiting toxicity in cycle 1 Main toxicities were infusion-related reactions (IRRs) — dyspnea (15%), chills (13%) and flushing (13%); hypotension requiring vasopressor support also observed Delayed hypersensitivity reactions (n = 14, mostly rash) also noted Protocol amended to require premedication with corticosteroids and antihistamines Premedication decreased severity of IRRs Pre-Amendment (N = 24) Post-Amendment (N = 30) With permission from LaCasce A et al. Proc ASH 2014;Abstract 293.

Response Best response n = 48 Objective response rate Complete remission Partial remission 46 (96%) 40 (83%) 6 (13%) Stable disease 1 (2%) Majority of complete remissions (34/40) achieved at Cycle 2 restage Stem cell mobilization and collection (n = 33) Median CD34+ cell yield (cells/kg): 4.0 x 106 (range 1.7-11.8) in a median of 2 apheresis sessions (range 1-5) Median time to platelet and neutrophil engraftment <2 weeks LaCasce A et al. Proc ASH 2014;Abstract 293.

Progression-Free Survival (PFS) Proportion of Patients Free of Progression/Death ASCT (n = 31) All patients (n = 48) Time (months) Median PFS not reached 4 progressions and 1 death subsequent to ASCT (8 events overall) Medians are not yet estimable for response duration With permission from LaCasce A et al. Proc ASH 2014;Abstract 293.

Author Conclusions B-vedotin in combination with bendamustine: Induced a response rate (83% complete response rate, 96% overall response rate) that compares favorably to historical data. Has a manageable safety profile with premedication for IRRs. Has had no adverse impact on stem cell mobilization or engraftment. This combination represents a promising salvage regimen for patients with HL who have relapsed/refractory disease after front-line therapy. Response durability continues to be assessed. LaCasce A et al. Proc ASH 2014;Abstract 293.

Investigator Commentary: B-Vedotin and Bendamustine for Relapsed/Refractory HL Back in 2013 we published results of a Phase II evaluation of single-agent bendamustine in relapsed/refractory HL. This study by LaCasce and colleagues is an interesting one that investigated the combination of bendamustine and B-vedotin for relapsed/refractory disease. The results of this study demonstrated a high overall response rate and complete remission rate with the combination of bendamustine and B-vedotin. Many patients who achieved a complete response after the first staging went to transplant. The number of stem cells collected was modest and lower than normal. I like the treatment, but I was not impressed by the PFS curves. At a short follow-up, the curves look fairly similar to the curves we observed in the AETHERA trial (ASH 2014;Abstract 673) investigating B-vedotin for patients at risk of relapse or disease progression after ASCT. The combination of bendamustine and B-vedotin caused a high frequency of IRRs. Though unusual, IRRs are known to occur with bendamustine, and they may also occur with B-vedotin. However, after the protocol was amended to include corticosteroid premedication the side effects with the combination were much more manageable. Interview with Craig Moskowitz, MD, January 6, 2015